Levoethin Stada (Ethinylestradiol, Levonorgestrel)

The two hormones act together on the hypothalamic‑pituitary‑ovarian axis. Ethinylestradiol suppresses follicle‑stimulating hormone, while levonorgestrel blocks the luteinizing hormone surge, preventing ovulation. Levonorgestrel also thickens cervical mucus and alters the endometrium, creating conditions unfavorable for implantation.

The specific dosing regimen for Levoethin Stada is determined by the prescribing clinician based on the product’s labeling and the patient’s individual needs. Typically, a combined oral contraceptive is taken once daily for a defined cycle, but the exact schedule should be confirmed with a healthcare professional.

Levoethin Stada is classified as pregnancy category X, meaning it must not be used during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding women, as hormonal exposure may affect milk production and infant health.

To order Levoethin Stada, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levoethin contains a standard dose of ethinylestradiol and levonorgestrel, offering efficacy comparable to other approved combined oral contraceptives. Differences among products usually relate to hormone dose, formulation excipients, and brand‑specific packaging, but all share the same core mechanism of preventing ovulation and implantation.

Levoethin Stada tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat and direct sunlight to maintain product stability throughout its shelf life.

Levoethin Stada is taken orally as a tablet, usually once each day at the same time, with or without food. Patients should follow the prescribing information for the specific cycle length (e.g., 21 active tablets followed by a placebo interval) as directed by their healthcare provider.

The most serious risks include venous thromboembolism, arterial thrombosis, severe hypertension, liver tumors and serious allergic reactions. Patients should seek immediate medical attention if they experience unexplained leg pain, chest discomfort, severe headache, visual changes, or signs of an allergic reaction.

Levoethin Stada is contraindicated in women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, known or suspected breast cancer, or who are smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.